Specialities

Nephrology

Hypertension and nephrology

FEBRUARY 26, 2022

[The safety and efficacy of LCP-tacrolimus in maintenance immunosuppressive therapy after kidney transplantation]

CSEPREKÁL Orsolya, KEGLEVICH András, REMPORT Ádám

[This paper provides a comprehensive review of a new, innovative formulation of one of the cornerstones of immunosuppressive maintenance therapy, tacrolimus (LifeCycle Pharma Tac, LCP-Tac, LCPT). This brief overview provides a deeper insight into the scientific literature of LCP-Tac. In summary, once daily LCP-Tac, a medication available in routine clinical practice, can provide effective and safe blood levels in renal transplant patients. Furthermore LCP-Tac may require lower doses of... tovább »

Hypertension and nephrology

FEBRUARY 26, 2022

[Beyond the blood sugar reduction. SGLT-2 inhibitors in kidney protection]

SIMONYI Gábor

[Results of cardiovascular safety studies with SGLT-2 inhibitors have shown that in addition to their hypoglycaemic and beneficial cardiovascular effects, they are renoprotective. A number of mechanisms underlying the renoprotective effects of SGLT-2 inhibitors have been shown to reduce albuminuria and deterioration of renal function. Their nephroprotective effects extend over a very wide range of eGFR and albuminuria categories. In the DAPA-CKD study, dapagliflozin was shown to exert its... tovább »

Hypertension and nephrology

FEBRUARY 26, 2022

[Lupus nephritis, 2022]

CZIROK Szabina, DOLGOS Szilveszter

[The lupus nephritis (LN) is one of the most frequent manifestation of SLE which causes higher morbiditiy and mortalitiy of the patients if it appears. Although the use of glucocorticoides, cyclophosphamide and mycofenolat mofetil and the protection of the kidney with conservative therapy has significantly improved the outcome of the disease, but the long-term renal outcome and risk of death from LN have not changes over the last 20 years. Furthermore, the side effect of our medications used as... tovább »

Lege Artis Medicinae

FEBRUARY 24, 2022

[Cardiovascular prevention 2021 – Guidelines of European Society of Cardiology 2021. Prevention at the population level And Disease specific cardiovascular prevention]

VÁLYI Péter, KÉKES Ede

[In our four-part publication we review the current state of cardiovascular prevention based on the European Society of Car­dio­logy Guidelines 2021. In part 1 we reviewed the risk factors, risk assessment, age-specificities, the influencing factors, including diabetes mellitus and chronic kidney disease. In part 2 we concerned comorbidities affecting the cardiovascular risk. In part 3 we reviewed the personalised cardiovascular prevention and the management of specific risk factors, including... tovább »

Hypertension and nephrology

DECEMBER 20, 2021

[Nonproteinuric diabetic kidney disease]

LENGYEL Zoltán, SCHANDL László

[Diabetic nephropathy is one of the most common causes of chronic kidney disease. In recent years, besides the classic phenotype with increased urinary albumin excretion, another phenotype showing Progressive kidney failure without albuminuria has been observed with increasing frequency. The histology, the pathophysiology and the course of non-proteinuric diabetic kidney disease differs from the classic phenotype in several respects. The former shows traits similar to atherosclerotic kidney... tovább »

Hypertension and nephrology

DECEMBER 20, 2021

[Extrapulmonary multiple organ damage and dysfunction in Covid-19]

KÉKES Ede, NAGY Judit

[SARS-CoV-2 virus attacks nőt only the lungs bút alsó many other or- gans (heart, kidney, liver, pancreas, gastrointestinal tract, brain, hematopoiesis) and regulatory system (RAAS, immuné system) to different degrees and with dif- ferent pathomechanisms. Accordingly, cell death, tissue damage and dysfunction or failure of somé organs has been developed. Our paper provides a detailed analysis of the incidence of extrapulmonary lesions, clinical manifestations, and the underlying... tovább »